CJRB 103
Alternative Names: CJRB-103; MRx-1299Latest Information Update: 19 Sep 2023
At a glance
- Originator 4D Pharma PLC
- Developer 4D Pharma PLC; CJ Bioscience
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Bacteria replacements; Histone deacetylase inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
- No development reported Glioblastoma; Neuroblastoma
Most Recent Events
- 19 Sep 2023 Preclinical trials in Solid tumours in South Korea (PO) (CJ Biosciences pipeline, September 2023)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Glioblastoma in United Kingdom (PO)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Neuroblastoma in United Kingdom (PO)